Michael J Robertson - JoVE Visualize

Showing results (61-70 of 104) with videos related to

Pageof 11

Sort By:

Vaccine|August 19, 2014

Activation of dendritic cell function by soypeptide lunasin as a novel vaccine adjuvantChun-Yu Tung, David E Lewis, Ling Han, et al.

The New England Journal of Medicine|January 6, 2021

Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host DiseaseSherif S Farag, Mohammad Abu Zaid, Jennifer E Schwartz, et al.

Nature|January 17, 2020

Structure of the M2 muscarinic receptor-β-arrestin complex in a lipid nanodiscDean P Staus, Hongli Hu, Michael J Robertson, et al.

Nature|December 22, 2025

Non-equilibrium snapshots of ligand efficacy at the μ-opioid receptorMichael J Robertson, Arnab Modak, Makaía M Papasergi-Scott, et al.

Nature|January 17, 2020

Structure of the neurotensin receptor 1 in complex with β-arrestin 1Weijiao Huang, Matthieu Masureel, Qianhui Qu, et al.

Leukemia & Lymphoma|July 15, 2006

Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysisKristen N Ganjoo, Caroline S An, Michael J Robertson, et al.

Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 27, 2013

A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphomaMichael J Robertson, Justin Kline, Herbert Struemper, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008

A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancerMichael J Robertson, John M Kirkwood, Theodore F Logan, et al.

Blood|October 15, 2011

Acquired STAT4 deficiency as a consequence of cancer chemotherapyIvan P Lupov, Larry Voiles, Ling Han, et al.

British Journal of Haematology|April 30, 2015

Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trialAndre Goy, Sevgi Kalayoglu Besisik, Johannes Drach, et al.

Pageof 11

Showing results (61-70 of 104) with videos related to

Sort By:

Pageof 11

Vaccine|August 19, 2014

Activation of dendritic cell function by soypeptide lunasin as a novel vaccine adjuvantChun-Yu Tung, David E Lewis, Ling Han, et al.

The New England Journal of Medicine|January 6, 2021

Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host DiseaseSherif S Farag, Mohammad Abu Zaid, Jennifer E Schwartz, et al.

Nature|January 17, 2020

Structure of the M2 muscarinic receptor-β-arrestin complex in a lipid nanodiscDean P Staus, Hongli Hu, Michael J Robertson, et al.

Nature|December 22, 2025

Non-equilibrium snapshots of ligand efficacy at the μ-opioid receptorMichael J Robertson, Arnab Modak, Makaía M Papasergi-Scott, et al.

Nature|January 17, 2020

Structure of the neurotensin receptor 1 in complex with β-arrestin 1Weijiao Huang, Matthieu Masureel, Qianhui Qu, et al.

Leukemia & Lymphoma|July 15, 2006

Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysisKristen N Ganjoo, Caroline S An, Michael J Robertson, et al.

Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 27, 2013

A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphomaMichael J Robertson, Justin Kline, Herbert Struemper, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008

A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancerMichael J Robertson, John M Kirkwood, Theodore F Logan, et al.

Blood|October 15, 2011

Acquired STAT4 deficiency as a consequence of cancer chemotherapyIvan P Lupov, Larry Voiles, Ling Han, et al.

British Journal of Haematology|April 30, 2015

Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trialAndre Goy, Sevgi Kalayoglu Besisik, Johannes Drach, et al.

Pageof 11